Home

GAIL BOUDREAUX

CIK 1287920 · President and CEO · last filed 2026-07-17

GAIL BOUDREAUX is a President and CEO who has filed 141 SEC Form 4 insider transactions across 9 companies since 2007. The most recent filing shows the insider bought $1.0M of ELV on Jul 17, 2026. Across all open-market trades the lifetime net is −$36.0M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $143.8M across reported positions. 44 SEC filings were submitted jointly with ZIMMER BIOMET HOLDINGS, INC.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$143.78M

Companies

9

Total Filings

141

Lifetime Open-Market Net

-$36.02M

Filer Profile

Reported Address
220 VIRGINIA AVENUE
INDIANAPOLIS, IN 46204
Related Filers
ZIMMER BIOMET HOLDINGS, INC. — 44 joint filings, latest 2021-04-02
UNITEDHEALTH GROUP INC — 33 joint filings, latest 2014-09-25
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
ELV President and CEO 169,991 $418.72 $71.18M -$13.59M 8 2026-07-17
TGT Director 12,192 $155.83 $1.90M $0 6 2026-03-13
Elevance Health, Inc. (ANTM) Delisted President and CEO 94,041 $482.58 $45.38M $2.00M 6 2022-03-03
ZBH Director 2,095 $93.49 $195.9K $250.0K 41 2021-04-02
ANTX President and CEO 11,104 $5.41 $60.1K $0 1 2018-03-05
XEL Director 1,780 $75.50 $134.4K $50.0K 29 2018-01-02
NVAX Director 10,000 $9.42 $94.2K $144.8K 4 2017-03-20
UNH EVP & CEO, UnitedHealthcare 184,731 $379.09 $70.03M -$24.88M 39 2014-09-25
GENZ Director 5,000 $38.13 $190.7K $0 6 2011-04-06

Recent Filings

141 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-07-17 ELV Buy (P) +2,725 $1.00M EDGAR
2026-03-13 TGT Grant (A) +2,682 $0 EDGAR
2026-03-04 ELV Mixed +18,231 -$2.47M EDGAR
2025-07-18 ELV Buy (P) +8,500 $2.44M EDGAR
2025-03-14 TGT Grant (A) +2,946 $0 EDGAR
2025-03-05 ELV Mixed +15,811 -$4.11M EDGAR
2024-07-23 ELV Sell (S) −34,000 -$17.03M EDGAR
2024-07-22 ELV Notice (144) −34,000 -$17.03M EDGAR
2024-03-15 TGT Grant (A) +1,873 $0 EDGAR
2024-03-05 ELV Mixed +23,676 -$9.61M EDGAR
Showing 1–10 of 141
Page 1 of 15
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.